Angiogenesis and anti-angiogenic therapy in prostate cancer
Authors:
- Deborah MukherjiDMDeborah Mukherji
- Sally TemrazSally Temraz
- David WehbeDWDavid Wehbe
- Ali ShamseddineASAli Shamseddine
- 1 August 2013
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 87 (2) , 122-131
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancerCancer, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Inhibition of angiopoietin‐2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viabilityThe Prostate, 2010
- A sex-specific role for androgens in angiogenesisJournal of Experimental Medicine, 2010
- Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975Annals of Oncology, 2009
- A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen AblationJournal of Urology, 2009
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic AgentsCancer Investigation, 2009